Designation: F 2150 – 02$^{\epsilon 1}$

Standard Guide for Characterization and Testing of Biomaterial Scaffolds Used in Tissue-Engineered Medical Products[1]

This standard is issued under the fixed designation F 2150; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

ε[1] NOTE—The designation, year date, and footnote 1 were editorially corrected in June 2002.

1. Scope

1.1 This guide is a resource of currently available test methods for the characterization of biomaterial scaffolds used to develop and manufacture tissue-engineered medical products (TEMPs).

1.2 The test methods contained herein guide characterization of the bulk physical, chemical, mechanical, and surface properties of a scaffold construct. Such properties may be important for the success of a TEMP, especially if they affect cell retention, activity and organization, the delivery of bioactive agents, or the biocompatibility and bioactivity within the final product.

1.3 This guide may be used as guidance in the selection of appropriate test methods for the generation of a raw material or original equipment manufacture (OEM) specification. This guide also may be used to characterize the scaffold component of a finished medical product.

1.4 This guide addresses natural, synthetic, or combination scaffold materials with or without bioactive agents or biological activity. This guide does not address the characterization or release profiles of any biomolecules, cells, drugs, or bioactive agents that are used in combination with the scaffold.

1.5 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory requirements prior to use.*

2. Referenced Documents

2.1 *ASTM Standards:*

D 412 Test Methods for Vulcanized Rubber and Thermoplastic Rubbers and Thermoplastic Elastomers—Tension[2]
D 570 Test Method for Water Absorption of Plastics[3]
D 638 Test Method for Tensile Properties of Plastics[3]
D 648 Test Method for Deflection Temperature of Plastics Under Flexural Load in the Edgewise Position[3]
D 671 Test Method for Flexural Fatigue of Plastics by Constant-Amplitude-of-Force[3]
D 695 Test Method for Compressive Properties of Rigid Plastics[3]
D 747 Test Method for Apparent Bending Modulus of Plastics by Means of a Cantilever Beam[3]
D 790 Test Methods for Flexural Properties of Unreinforced and Reinforced Plastics and Electrical Insulating Materials[3]
D 792 Test Methods for Density and Specific Gravity (Relative Density) of Plastics by Displacement[3]
D 882 Test Method for Tensile Properties of Thin Plastic Sheeting[3]
D 1042 Test Method for Linear Dimensional Changes of Plastics Under Accelerated Service Conditions[3]
D 1238 Test Method for Flow Rates of Thermoplastics by Extrusion Plastometer[3]
D 1388 Test Method for Stiffness of Fabrics[4]
D 1621 Test Method for Compressive Properties of Rigid Cellular Plastics[3]
D 1623 Test Method for Tensile and Tensile Adhesion Properties of Rigid Cellular Plastics[3]
D 1708 Test Method for Tensile Properties of Plastics by Use of Microtensile Specimens[3]
D 1898 Practice for Sampling of Plastics[5]
D 2857 Practice for Dilute Solution Viscosity of Polymers[6]
D 2873 Test Method for Interior Porosity of Poly(Vinyl Chloride) (PVC) Resins by Mercury Intrusion Porosimetry[6]
D 2990 Test Methods for Tensile, Compressive, and Flexural Creep and Creep-Rupture of Plastics[6]
D 3016 Practice for Use of Liquid Exclusion Chromatography Terms and Relationships[6]
D 3039/D 3039M Test Method for Tensile Properties of

[1] This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.43 on Tissue Engineered Biomaterials.
Current edition approved Jan. 10, 2002. Published January 2002.
[2] *Annual Book of ASTM Standards*, Vol 09.01.
[3] *Annual Book of ASTM Standards*, Vol 08.01.
[4] *Annual Book of ASTM Standards*, Vol 07.01.
[5] Discontinued 1998; see 1997 *Annual Book of ASTM Standards*, Vol 08.01.
[6] *Annual Book of ASTM Standards*, Vol 08.02.

Polymer Matrix Composite Materials[7]
D 3417 Test Method for Enthalpies of Fusion and Crystallization of Polymers by Differential Scanning Calorimetry (DSC)[6]
D 3418 Test Method for Transition Temperatures of Polymers by Differential Scanning Calorimetry[6]
D 4001 Test Method for Determination of Weight-Average Molecular Weight of Polymers by Light Scattering[6]
D 4404 Test Method for Determination of Pore Volume and Pore Volume Distribution of Soil and Rock by Mercury Intrusion Porosimetry[8]
D 4603 Test Method for Determining Inherent Viscosity of Poly(Ethylene Terephthalate) (PET) by Glass Capillary Viscometer[9]
D 5226 Practice for Dissolving Polymer Materials[9]
D 5296 Test Method for Molecular Weight Averages and Molecular Weight Distribution of Polystyrene by High Performance Size-Exclusion Chromatography[9]
D 5732 Test Method for Stiffness of Nonwoven Fabrics Using the Cantilever Test[10]
D 6125 Test Method for Bending Resistance of Paper and Paperboard (Gurley Type Tester)[11]
D 6420 Test Method for Determination of Gaseous Organic Compounds by Direct Interface Gas Chromatography-Mass Spectrometry[12]
D 6474 Test Method for Determining Molecular Weight Distribution and Molecular Weight Averages of Polyolefins by High Temperature Gel Permeation Chromatography[9]
D 6539 Test Method for Measurement of Pneumatic Permeability of Partially Saturated Porous Materials by Flowing Air[13]
D 6579 Practice for Molecular Weight Averages and Molecular Weight Distribution of Hydrocarbon and Terpene Resins by Size-Exclusion Chromatography[14]
E 128 Test Method for Maximum Pore Diameter and Permeability of Rigid Porous Filters for Laboratory Use[15]
E 177 Practice for Use of the Terms Precision and Bias in ASTM Test Methods[16]
E 456 Terminology for Relating to Quality and Statistics[16]
E 473 Terminology Relating to Thermal Analysis[16]
E 691 Practice for Conducting an Interlaboratory Study to Determine the Precision of a Test Method[16]
E 793 Test Method for Enthalpies of Fusion and Crystallization by Differential Scanning Calorimetry[16]
E 794 Test Method for Melting and Crystallization Temperatures By Thermal Analysis[16]
E 967 Practice for Temperature Calibration of Differential Scanning Calorimeters and Differential Thermal Analyzers[16]
E 968 Practice for Heat Flow Calibration of Differential Scanning Calorimeters[16]
E 996 Practice for Reporting Data in Auger Electron Spectroscopy and X-Ray Photoelectron Spectroscopy[17]
E 1078 Guide for Procedures for Specimen Preparation and Mounting in Surface Analysis[17]
E 1142 Terminology Relating to Thermophysical Properties[16]
E 1294 Test Method for Pore Size Characteristics of Membrane Filters Using Automated Liquid Porosimeter[18]
E 1298 Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products[18]
E 1356 Test Method for Assignment of the Glass Transition Temperatures by Differential Scanning Calorimetry or Differential Thermal Analysis[16]
E 1642 Practice for General Techniques of Gas Chromatography Infrared (GC/IR) Analysis[17]
E 1829 Guide for Handling Specimens Prior to Surface Analysis[17]
F 151 Test Method for Residual Solvents in Flexible Barrier Materials[11]
F 316 Test Method for Pore Size Characteristics of Membrane Filters by Bubble Point and Mean Flow Pore Test[19]
F 748 Practice for Selecting Generic Biological Test Methods for Materials and Devices[20]
F 1249 Test Method for Water Vapor Transmission Rate Through Plastic Film and Sheeting Using a Modulated Infrared Sensor[11]
F 1251 Terminology Relating to Polymeric Biomaterials in Medical and Surgical Devices[20]
F 1634 Practice for In-Vitro Environmental Conditioning of Polymer Matrix Composite Materials and Implant Devices[20]
F 1635 Test Method for In Vitro Degradation Testing of Poly (L-lactic Acid) Resin and Fabricated Form for Surgical Implants[20]
F 1884 Test Method for Determining Residual Solvents in Packaging Materials[11]
F 1980 Guide for Accelerated Aging of Sterile Medical Device Packages[11]
F 1983 Practice for Assessment of Compatibility of Absorbable/Resorbable Biomaterials for Implant Applications[11]
F 2025 Practice for Gravimetric Measurement of Polymeric Components for Wear Assessment[20]
F 2027 Guide for Characterization and Testing of Substrate Materials for Tissue-Engineered Medical Products[20]
G 120 Practice for Determination of Soluble Residual Contamination in Materials and Components by Soxhlet Extraction[15]

[7] *Annual Book of ASTM Standards*, Vol 15.03.
[8] *Annual Book of ASTM Standards*, Vol 04.08.
[9] *Annual Book of ASTM Standards*, Vol 08.03.
[10] *Annual Book of ASTM Standards*, Vol 07.02.
[11] *Annual Book of ASTM Standards*, Vol 15.09.
[12] *Annual Book of ASTM Standards*, Vol 11.03.
[13] *Annual Book of ASTM Standards*, Vol 04.09.
[14] *Annual Book of ASTM Standards*, Vol 06.03.
[15] *Annual Book of ASTM Standards*, Vol 14.04.
[16] *Annual Book of ASTM Standards*, Vol 14.02.
[17] *Annual Book of ASTM Standards*, Vol 03.06.
[18] *Annual Book of ASTM Standards*, Vol 11.05.
[19] Discontinued 1995; see 1994 *Annual Book of ASTM Standards*, Vol 11.02.
[20] *Annual Book of ASTM Standards*, Vol 13.01.

2.2 *AAMI Standards:*

AAMI STBK9-1 Sterilization—Part 1: Sterilization in Health Care Facilities[21]

AAMI STBK9-2 Sterilization—Part 2: Sterilization Equipment[21]

AAMI STBK9-3 Sterilization—Part 3: Industrial Process Control[21]

2.3 *ANSI Standards:*

ANSI/ISO/ASQ Q9000-2000: Quality Management Systems—Fundamentals and Vocabulary[22]

ANSI/ISO/ASQ Q9001-2000: Quality Management Systems: Requirements[22]

2.4 *British Standards Institute:*

British Standard—Animal Tissues and Their Derivatives Utilized in the Manufacture of Medical Devices—Part 1: Analysis and Management of Risk (EN 12442-1) [22]

British Standard—Animal Tissues and Their Derivatives Utilized in the Manufacture of Medical Devices—Part 2: Controls on Sourcing, Collection, and Handling (EN 12442-2) [22]

British Standard—Animal Tissues and Their Derivatives Utilized in the Manufacture of Medical Devices—Part 3: Validation of the Elimination and/or Inactivation of Viruses and Transmissible Agents (EN 12442-3) [22]

2.5 *ISO Standards:*

ISO 1133-1991 Determination of the Melt-Mass Flow Rate (MFR) and the Melt Volume-Flow Rate (MVR) of Thermoplastics[22]

ISO 10993-9 Biological Evaluation of Medical Devices—Part 9: Degradation of Materials Related to Biological Testing[22]

ISO 10993-13 Biological Evaluation of Medical Devices—Part 13: Identification and Quantification of Degradation Products from Polymers[22]

ISO 10993-14 Biological Evaluation of Medical Devices—Part 14: Identification and Quantification of Degradation Products from Ceramics[22]

ISO 10993-15 Biological Evaluation of Medical Devices—Part 15: Identification and Quantification of Degradation Products from Coated and Uncoated Metals and Alloys[22]

ISO 11357-1 Plastics—Differential Scanning Calorimetry (DSC)—Part 1: General Principles[22]

ISO 11357-2 Plastics—Differential Scanning Calorimetry (DSC)—Part 2: Determination of Glass Transition Temperature[22]

2.6 *U.S. Code of Federal Regulations:*

Title 21—Food and Drugs Services, Part 820—Quality System Regulation (21 CFR Part 820) [23]

2.7 *U.S. Pharmacopeia (USP) Standards:*

Source: General Tests and Assays—USP24/NF19, Jan. 1, 2000 [24]

3. Terminology

3.1 Unless provided otherwise in 3.2, terminology shall be in conformance with Terminology F 1251.

3.2 *Definitions:*

3.2.1 *bioactive agents*, *n*—any molecular component in, on, or with the interstices of a device that is intended to elicit a desired tissue or cell response. Growth factors, antibiotics, and antimicrobials are typical examples of bioactive agents. Device structural components or degradation byproducts that evoke limited localized bioactivity are not included.

3.2.2 *pores*, *n*—an inherent or induced network of channels and open spaces within an otherwise solid structure.

3.2.3 *porometry*, *n*—the determination of the distribution of pore diameters relative to direction of fluid flow by the displacement of a wetting liquid as a function of pressure.

3.2.4 *porosimetry*, *n*—the determination of pore volume and pore size distribution through the use of a nonwetting liquid (typically mercury) intrusion into a porous material as a function of pressure.

3.2.5 *porosity*, *n*—property of a solid which contains an inherent or induced network of channels and open spaces. Porosity can be measured by the ratio of pore (void) volume to the apparent (total) volume of a porous material and is commonly expressed as a percentage.

3.2.6 *scaffold*, *n*—a support, delivery vehicle, or matrix for facilitating the migration, binding, or transport of cells or bioactive molecules used to replace, repair, or regenerate tissues.

3.2.6.1 *Discussion*—ASTM Committee F04 is continuing to refine definitions for the terms tissue engineering, tissue-engineered medical products (TEMPs), and scaffold. Final definitions will be from consideration of Committee F04 and other resources such as *The Williams Dictionary of Biomaterials* (**9**) and will be balloted at a later date.

4. Summary of Guide

4.1 The physicochemical and three-dimensional characteristics of the scaffold material are expected to influence the properties of TEMPs. It is the intent of this guide to provide a compendium of materials characterization techniques for properties that may be related directly to the functionality of scaffolds for TEMPs.

4.2 Numerous general areas of characterization also should be considered when developing a scaffold for TEMPs. Among these are compositional identity, physical and chemical properties or characteristics, viable sterilization techniques, degradability/resorbability, and mechanical properties.

4.3 Application of the test methods contained within this guide do not guarantee clinical success of a finished product but will help to ensure consistency in the properties and characterization of a given scaffold material.

[21] Available from the Association for the Advancement of Medical Instrumentation, 1110 N. Glebe Rd., Suite 220, Arlington, VA 22201-4795.

[22] Available from American National Standards Institute, 25 W. 43rd St., 4th Floor, New York, NY 10036.

[23] Available from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20593.

[24] Available from U.S. Pharmacopeia, 12601 Twinbrook Pkwy., Rockville, MD 20852. The standards will be listed by appropriate USP citation number. Succeeding USP editions alternately may be referenced.

4.4 This guide does not suggest that all of the listed tests be conducted. The decision regarding applicability or suitability of any particular test method remains the responsibility of the supplier, user, or regulator of the scaffold material based on applicable regulations, characterizations, and preclinical/clinical testing.

5. Significance and Use

5.1 Scaffolds potentially may be metallic, ceramic, polymeric, natural, or composite materials. Scaffolds may be solid or porous, mechanically rigid or gelatinous, absorbable/degradable, or nonresorbable/nondegradable. The scaffold may or may not have a surface treatment. Because of this large breadth of possible substrate materials and scaffold constructions, this guide cannot be considered as exhaustive in its listing of potentially applicable tests. A voluntary guidance for the development of tissue-engineered products can be found in Omstead, et al (**1**).[25]

5.2 Each TEMP scaffold product is unique and may require testing not within the scope of this guide or other guidance documents. Users of this guide are encouraged to examine the references listed herein and pertinent FDA or other regulatory guidelines or practices, and conduct a literature search to identify other procedures particularly pertinent for evaluation of their specific scaffold material (**2,3,4**). It is the ultimate responsibility of the TEMP scaffold designer to determine the appropriate testing, whether or not it is described in this guide.

5.3 A listing of potentially applicable substrate specific tests may be found in Guide F 2027, with additional tests listed in X1.4 of this guide. Other unique characterization procedures may also be relevant and not covered by this guide.

6. Chemical Properties and Tests

NOTE 1—Chemical properties are the chemical composition characteristics of a compound. Chemical tests provide information about the identity or nature of the chemical components of a scaffold. Chemical tests include those that provide information about the nature or size of constituent molecules, the product's purity, or the chemical nature of the scaffold surface.

6.1 *Identification of Impurities*:

6.1.1 Chemical impurities are expected and unexpected contamination that is not part of the intended design of the scaffold. Acceptable levels of impurities are a function of the nature of the contamination and the scaffold's intended in vitro or in vivo application. A more precise definition of both contaminants and impurities and guidance regarding their significance may be found in Guide E 1298.

6.1.2 Expected impurities of potential biological significance should be monitored through appropriate analytic means. Such typical impurities may include, but are not limited to processing aids or solvents, unreacted cross-linking agents, residual monomers, endotoxins, sterilization residuals, and residual solutions used in the production of collagen, elastin, or other naturally derived products that, by their chemical nature or relative concentrations, carry potential for influencing cell or tissue response.

6.1.3 Impurities may be identified or quantitatively determined by infrared (IR) spectroscopy, nuclear magnetic resonance (NMR), combined gas chromatography/mass spectrometry (GC/MS), or other analytic methods as appropriate.

6.1.4 Generally, impurities are isolated more readily when the scaffold in its entirety can be solvated along with possible contaminants. If the scaffold cannot be dissolved, extraction in appropriate solvents becomes indicated.

6.1.4.1 *Solvation/Dissolution*—In the absence of known or established dissolution solvents for a particular substrate, Practice D 5226 may be referred to deliver added guidance in identifying suitable potential solvents for dissolving a scaffold material. Note that samples cannot be dissolved in analytic solvents that can also be considered as potential contaminants or create analytic interferences.

6.1.4.2 Extraction of residuals may be undertaken by utilization of methods such as Practice G 120. The extract then may be concentrated and analyzed by appropriate chromatographic analysis.

6.1.5 The amount of any expected impurity should be quantified and the analytic detection limit reported. Both solvated and extracted samples should provide results that specify the amount of expected impurity per mass of test sample in either percentage, ppm (µg/g;mg/kg), or ppb (ng/g;µg/kg) units.

6.1.6 The following analytic methods may be applicable in the determination and quantification of potential impurities:

6.1.6.1 Gas chromatography (GC) is best used for the routine detection of volatile relatively low molecular weight impurities or contaminants. Some methods that may prove suitable include Test Methods F 151 and F 1884.

6.1.6.2 Gas chromatography can be coupled with both quantitative and qualitative analytic methods such as infrared spectrophotometry (IR) or mass spectroscopy (MS) to provide compositional identification while quantitatively detecting low molecular weight volatile impurities or contaminants. Some particular methods that may prove useful include Test Method D 6420 and Practice E 1642.

6.2 *Molecular Weight Determination*:

6.2.1 For polymeric materials (synthetic or natural), the molecular weight and molecular weight distribution may be determined through size exclusion chromatography (SEC) or gel permeation chromatography (GPC). Other procedures such as inherent or intrinsic viscosity, light scattering, or membrane osmometry may be used.

6.2.2 In any of the preceding tests, the solvent solubility characteristics of the scaffold will be highly significant in allowing determination of suitable molecular weight test methods. In the absence of known or established dissolution solvents for a particular scaffold substrate, Practice D 5226 provides added guidance in identifying suitable potential solvents for dissolving a substrate material.

6.2.3 The following test methods may be applicable in the determining the molecular weight of the fabricated scaffold.

NOTE 2—The following GPC/SEC and IV methods are considered to be suitable for use on linear polymer systems only. Branched polymer systems should use light-scattering techniques.

[25] The boldface numbers in parentheses refer to the list of references at the end of this standard.

6.2.3.1 *Gel Permeation Chromatography (GPC), Also Known as Size Exclusion Chromatography (SEC)*—See Test Methods D 5296 and D 6474 and Practices D 3016 and D 6579.

NOTE 3—The SEC solvent system and calibration standard polymer type should be specified with any obtained result.

6.2.3.2 *Inherent Viscosity*—See Practice D 2857 and Test Method D 4603.

NOTE 4—The test temperature, solvent system, and sample concentration should be included with any reported result.

6.2.3.3 *Light Scattering*—See Test Method D 4001.

NOTE 5—This test method is suitable for both linear and branched polymer systems.

TABLE 1 USP Chemical Tests

USP 24-Test No.	Test Description	USP 24-Pages
<197>	Spectrophotometric identification	1855–1856
<231>	Heavy metals	1858–1859
<381>	Elastomeric closures for injections—physicochemical test procedures	1867–1868
<731>	Loss in drying (water content)	1954
<736>	Mass spectroscopy-purity or elemental analysis	1954–1958
<761>	Nuclear magnetic resonance-purity or component analysis (for example, copolymers)	1959–1965
<851>	Spectrophotometry and light scattering-(molecular weight information)	1992–1997
<891>	Thermal analysis (purity)	1999–2000
<911>	Viscosity (molecular weight)	2002–2005
<921>	Water determination	2003–2005

6.2.3.4 *Melt Flow*—If a substrate is found insoluble after utilizing the guidance contained within Practice D 5226, melt rheology (melt flow rate) may replace the measurements of solution properties to obtain an indication of the material's molecular weight and molecular weight distributions. Potentially useful methods include Test Method D 1238 and ISO 1133–1991.

6.3 *USP Chemical Tests*—See Table 1.

7. Physical Properties and Tests

NOTE 6—Physical properties are those of a compound that can change without involving a change in chemical composition.[26] Physical testing determines the physical properties of materials based on observation and measurement. Such tests include those that provide information about the porosity, density, crystallinity, or physical surface properties of a scaffold material.

7.1 *Porosity Characterization*—The following test methodologies are recommended for consideration in the evaluation and characterization of the porosity of scaffolds to be used for TEMPs (see X1.2 of this guide for further discussion on the nature, significance, and potential applicability of these test methods):

7.1.1 *Porosimetry (Liquid Intrusion)*—Methodology suitable for the mercury intrusion measurement of porosity include Test Methods D 2873 and D 4404.

7.1.2 The sample data recommended to be obtained and reported are as follows:

Median pore diameter and standard deviation (based on volume)—in μm
Pore diameter range or distribution—in μm
Total intrusion (void) volume—in cm^3/g
Bulk density—in g/cm^3
Total percentage porosity

$$\frac{\text{Total intrusion (void) volume, cm}^3\text{/g}}{\text{1/ bulk density, g/cm}^3} \times 100 = \text{total \% porosity}$$

7.1.3 *Porometry*—Methodology suitable for the capillary flow measurement of porosity include Test Methods E 128, E 1294, and F 316.

7.1.4 The sample data recommended to be obtained and reported are maximum or bubble point pore diameter (in microns); mean flow pore diameter (in microns); and pore size range or distribution, or both, (in microns).

7.1.5 *Pneumatic Permeability*—The methodology suitable for measurement of the pneumatic permeability of a scaffold structure includes Test Method D 6539.

7.1.5.1 The sample data recommended to be obtained and reported is as follows:

Average coefficient of pneumatic permeability—report in darcy (0.99 μm^2) or millidarcy (0.000 99 μm^2)

NOTE 7—In each of the aforementioned porosity, porometry, and permeability tests, bulkier samples may require modification into a thinner profile to allow proper specimen placement into the apparatus (for example, microtome or other sectioning techniques). In such situations, the specimen thickness should be adjusted to be as thick as practical and the test thickness as tested reported with the result. If the sample is anisotropic in nature, separate porometry or permeability sampling profiles for each orientation is recommended.

7.2 Glass transition temperatures, melting temperatures, and crystallinity may have an effect on the mechanical properties of the scaffold. Measurement of these properties may be appropriate to ensure consistency in mechanical properties and to identify batch to batch variations of scaffold materials.

7.2.1 Methodology that may be suitable for DSC measurement of glass transition and melting temperatures, or crystallinity of scaffolds include Test Methods D 3417, D 3418, E 793, E 794, E 1356, Terminologies E 473 and E 1142, and Practices E 967 and E 968. Other potentially relevant standards include ISO 11357–1 and 11357–2.

NOTE 8—Crystallinity also may be measured by X-ray diffraction.

7.3 *USP Physical Tests*—See Table 2.

7.4 *Other Physical Tests*:

7.4.1 Water absorption characteristics may be evaluated using Test Method D 570.

7.4.2 Density may be assessed using Test Methods D 792 if not evaluated within a porosimetry method as described in 7.1.1.

7.4.3 *Surface Properties*—The extent of surface characterization of scaffold substrates will depend on the nature of the scaffold material and its particular use. Users are encouraged to consider Ratner, et al (**5,6**) for guidance into the methods of

[26] S. P. Parker, Ed., *McGraw Hill Dictionary of Scientific and Technical Terms*, McGraw Hill Book Company, New York, third edition, 1984.

TABLE 2 USP Physical Tests

USP 24-Test No.	Test Description	USP 24-Pages
<616>	Bulk density and tapped density	1913–1914
<661>	Containers—biological tests (PET, PE and Ophthalmic polymers)	1930–1936
<699>	Density of solids	1940
<701>	Disintegration	1941
<741>	Melting range or temperature	1958–1959
<776>	Optical microscopy	1965–1967
<786>	Particle size distribution by analytical sieving	1969-1970
<846>	Specific surface area	1990–1992
<941>	X-ray diffraction—crystallinity	2005–2007
<1045>	Biotechnology derived articles (may be useful for natural materials)	2011–2026
<1181>	Scanning electron microscopy (characterization of surfaces)	2125–2128

surface characterization of scaffold substrates. Other methods that may be pertinent include Guides E 1078 and E 1829, and Practice E 996.

7.4.4 *Vapor Permeability of Films*—In the event the scaffold is constructed in the form of a film, vapor permeability may be determined using Test Method F 1249. Reference (**7**) also contains methods potentially useful in determining film permeability.

8. Mechanical Properties and Tests

NOTE 9—Mechanical properties are those which involve a relationship between stress and strain or provide a reaction to an applied physical force.[26]

8.1 Mechanical evaluations should preferentially occur in an environment similar to the expected service condition or expected condition of use. Sample preconditioning may be needed and can be conducted as described in Practice F 1634. In vitro conditioning typically employs buffered saline solutions at 37°C as described in Test Method F 1635.

8.2 Special mounting of specimens may be necessary dependent on configuration of the scaffold and measurement equipment variety and dimensions.

8.3 *Compressive Properties*—Dependent on a scaffold's physical or dimensional characteristics, its compressive properties may be evaluated using methodology found in one or more of the following Test Methods: D 695 and D 1621.

8.4 *Tensile Properties*—Dependent on a scaffold's physical or dimensional characteristics, its tensile properties may be evaluated using methodology found in one or more of the following Test Methods: D 412, D 638, D 882, D 1623, D 1708, and D 3039/D 3039M.

8.5 *Flexural/Bending Properties*—Dependent on a scaffold's physical or dimensional characteristics, its flexural properties may be evaluated using methodology found in one or more of the following Test Methods: D 648, D 671, D 747, D 790, D 1388, D 5732, and D 6125.

8.6 *Creep Characteristics*—If a scaffold is to be used in applications in which it is expected to maintain its mechanical properties while under constant strain, methodology found in Test Methods D 2990 may be useful.

8.7 *USP Mechanical Tests*—See Table 3.

TABLE 3 USP Mechanical Test

USP 24-Test No.	Test Description	USP 24-Pages
<881>	Tensile strengths (fibers or films)	1998–1999

9. Biological Tests and Evaluations

9.1 For many biomaterials, the in vivo response has been thoroughly characterized by way of both clinical use and long-term evaluations in laboratory animals. When new applications of a biomaterial or modifications to the physical form of the biomaterial are being considered, then the recommendations and test methods described within the following Practices should be considered: F 748 and F 1983.

9.1.1 *ISO 10993*—This standard contains a series of parts, each of which can assist the user dependent on evaluation needs. Particularly relevant selections for consideration in the characterization of TEMP scaffolds include the following:

9.1.1.1 *Part 1*—Evaluation and testing;

9.1.1.2 *Part 3*—Tests for genotoxicity, carcinogenicity, and reproductive toxicity;

9.1.1.3 *Part 5*—Tests for cytotoxicity: in vitro methods;

9.1.1.4 *Part 6*—Tests for local effects after implantation;

9.1.1.5 *Part 9*—Framework for the identification and quantification of potential degradation products;

9.1.1.6 *Part 10*—Tests for irritation and sensitization;

9.1.1.7 *Part 11*—Tests for systemic toxicity;

9.1.1.8 *Part 12*—Sample preparation and reference materials;

9.1.1.9 *Part 13*—Identification and quantification of degradation products from polymeric medical devices; and

9.1.1.10 *Part 16*—Toxicokinetic study design for degradation products and leachables.

9.1.2 *USP-24: <1074> and <1078>*—These two references offer guidance for safety evaluation of and good manufacturing practices (GMP) for pharmaceutical excipients. These tests can be generally applied to medical materials used for TEMP scaffolds.

9.1.3 Further but more specific guidance may be indicated depending on the composition or intended use of the product. Examples of pertinent supplemental guidance are as follows:

9.1.3.1 *USP -24:<1045> to <1050>*—This series provides guidance for the proper characterization and assessment of biotechnology derived articles or products.

9.1.3.2 *British Standard—Animal Tissues and Their Derivatives Used in the Manufacture of Medical Devices, Parts 1 and 3*—This series addresses the special evaluation requirements of animal-derived products, for example, hyaluronic acid, collagen, gelatin, and ascites-derived monoclonal antibodies.

9.1.4 *Impurities*—A definition of biological contaminants and impurities and guidance regarding their detection and significance may be found in Guide E 1298. Additional guidance and tests regarding biological impurities include USP 24: <85>—Bacterial Endotoxin; Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices; and Interim Guidance for Human and Veterinarian Drug Products and Biologicals—Kinetic LAL Techniques.